Fig. 1



E1/E3 minus
E4
E2
WT-Ad5
E1A
E1B
E2
E3
E4
12S, 13S
CR1
CR2
CR3
1
40
80
120
139
188
289
12S
186
dl520
E1A*

Fig. 2




Fig. 3



E1/E3-minus Ad5
40 pfu/cell
10 pfu/cell
not infected
not infected
40 pfu/cell
10 pfu/cell
dl520

Fig. 4



E1/E3-minus Ad5
40 pfu/cell
10 pfu/cell
not infected
not infected
40 pfu/cell
10 pfu/cell
dl520

Fig. 5




Fig. 6





Fig. 7


WT-AD5
N
CR1
CR2
CR3
C
1
40
80
120
139
188
289
dl520
N
CR1
CR2
C
1
40
80
120
139
186
289
dl1119/1131
N
1 3
CR3
C
139
218



pfu/ml
1,0E+07
1,0E+06
1,0E+05
1,0E+04
AdYB-1
AdYB-1 + pE4orf6
AdYB-1 + Ad-55K
AdYB-1 + pE4orf6 + Ad-55K

Fig. 8

times

Fig. 9



25
20
15
10
5
0
AdYB-1
AdYB-1 +E4orf6
AdYB-1 +E1B-55k
AdYB-1 +E1B-55k +E4orf6

Fig. 10





Fig. 11

Control:
No Daunorubicin



Daunorubicin:
40 ng/ml





Fig. 12


△: Hela/PBS
▲: HeLa/dl520
□: RDB257/PBS
■: RDB257/dl520
5 x 10⁸
Volume (mm³)
Days
0
500
1000
1500
2000
2500
0
5
10
15
20
25
30
35





Fig. 13

Fig. 14



Southern Blot Analysis

Fig. 15



10000000000
1000000000
100000000
10000000
1000000
100000
10000
Pfu/ml
HeLa/MT
HeLa/520
U2OS/MT
U2OS/520
181RDB/MT
181RDB/520
257RDB/MT
257RDB/520

Fig. 16



Wildtype Adenovirus
E1
MLP
E2B
E2A
E3
E4
Xvir03
E1
MLP
E2B
E2A
E3
E4
CMV-
Promoter
E1B55k - IRES – E4orf6

Fig. 17



Spec.
Prom.
Apoptosis-inducing genes
Prodrug genes
siRNA
Tumor suppressor genes
Cytokines
Xvir03/01
E1
MLP
E3
E2B
E2A
E4
CMV-
Promoter
E1B55k - IRES – E4orf6

Fig. 18A




Fig. 18B




Fig. 19

Northern Blot Analysis of E2 gene expression in Ad312 infected cells




Fig. 20

Northern Blot Analysis of E2 gene expression in infected cells




Fig. 21

XvirPSJL1





Fig. 22

XvirPSJL2



HeLa cells infected with different MOIs of dl520






Fig. 23

Fig. 24




Fig. 25
10000
1000
100
10
AYB-2days
AYB-2days
Ab312-2days
Ab312-2days
AYB-5days
AYB-5days
Ab312-5days
Ab312-5days

SEQUENCE LISTING

<110> Holm, Per Sonne

<120> Novel adenoviruses, nucleic acid coding therefor, and use thereof

<130> SP6833A

<140> PCT/EP 03/11427
<141> 2003-10-15

<160> 8

<170> PatentIn version 3.1

<210> 1
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for binding to YB-1

<400> 1
tgaggctgat tggctgggca
20

<210> 2
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for the manufacture of the detection probe for the KpnI fragment within the E2A coding Ad 5 sequence

<400> 2
gtcggagatc agatccgcgt
20

<210> 3
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for the manufacture of the detection probe for the KpnI fragment within the E2A coding Ad 5 sequence

<400> 3
gatcctcgtc gtcttcgctt
20

<210> 4
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for the manufacture of the detection probe for the KpnI fragment within the E2A coding Ad 5 sequence

<400> 4
gtcggagatc agatccgcgt
20

<210> 5
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for the manufacture of the detection probe for the KpnI fragment within the E2A coding Ad 5 sequence

<400> 5
gatcctcgtc gtcttcgctt
20

<210> 6
<211> 18
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for the manufacture of the probe binding between the E2 early and the E2 late promoter

<400> 6
agctgatctt cgcttttg
18

<210> 7
<211> 22
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> Probe for the manufacture of the probe binding between t
he E2 early and the E2 late promoter

<400> 7
ggatagcaag actctgacaa ag
22

<210> 8
<211> 1260
<212> DNA
<213> Adenovirus type 37

<220>
<221> misc_feature
<223> Part of the adenoviral E2 region with the YB-1 binding s
ites

<400> 8
aggaacttta tcctagagcg ctcaggaatc ttgcccgcca cctgctgtgc acttccta
gc 60

gactttgtgc ccattaagta ccgcgaatgc cctccgccgc tttggggcca ctgctacc
tt 120

ctgcagctag ccaactacct tgcctaccac tctgacataa tggaagacgt gagcggtg
ac 180

ggtctactgg agtgtcactg tcgctgcaac ctatgcaccc cgcaccgctc cctggttt
gc 240

aattcgcagc tgcttaacga aagtcaaatt atcggtacct ttgagctgca gggtccct
cg 300

cctgacgaaa agtccgcggc tccggggttg aaactcactc cggggctgtg gacgtcgg
ct 360

taccttcgca aatttgtacc tgaggactac cacgcccacg agattaggtt ctacgaag
ac 420

caatcccgcc cgccaaatgc ggagcttacc gcctgcgtca ttacccaggg ccacattc
tt 480

ggccaattgc aagccatcaa caaagcccgc caagagtttc tgctacgaaa gggacggg
gg 540

gtttacttgg acccccagtc cggcgaggag ctcaacccaa tccccccgcc gccgcagc
cc 600

tatcagcagc agccgcgggc ccttgcttcc caggatggca cccaaaaaga agctgcag
ct 660

gccgccgcca cccacggacg aggaggaata ctgggacagt caggcagagg aggttttg
ga 720

cgaggaggag gaggacatga tggaagactg ggagagccta gacgaggaag cttccgag
gt 780

cgaagaggtg tcagacgaaa caccgtcacc ctcggtcgca ttcccctcgc cggcgccc
ca 840

gaaatcggca accggttcca gcatggctac aacctccgct cctcaggcgc cgccggca
ct 900

gcccgttcgc cgacccaacc gtagatggga caccactgga accagggccg gtaagtcc
aa 960

gcagccgccg ccgttagccc aagagcaaca acagcgccaa ggctaccgct catggcgc
gg 1020

gcacaagaac gccatagttg cttgcttgca agactgtggg ggcaacatct ccttcgcc
cg 1080

ccgctttctt ctctaccatc acggcgtggc cttcccccgt aacatcctgc attactac
cg 1140

tcatctctac agcccatact gcaccggcgg cagcggcagc ggcagcaaca gcagcggc
ca 1200

cacagaagca aaggcgaccg gatagcaaga ctctgacaaa gcccaagaaa tccacagc
gg 1260